Exelixis Q2 2021 Earnings Report
Key Takeaways
Exelixis announced a 59 percent year-over-year increase in CABOMETYX net product revenue growth and record total revenues. The company is raising its net product and total revenue guidance for 2021.
Total revenues for the quarter ended June 30, 2021 were $385.2 million, compared to $259.5 million for the comparable period in 2020.
Net product revenues for the quarter ended June 30, 2021 were $284.2 million, compared to $178.7 million for the comparable period in 2020.
GAAP net income for the quarter ended June 30, 2021 was $96.1 million, or $0.30 per share, diluted, compared to GAAP net income of $66.8 million, or $0.21 per share, diluted, for the comparable period in 2020.
Non-GAAP net income for the quarter ended June 30, 2021 was $117.9 million, or $0.37 per share, diluted, compared to non-GAAP net income of $79.4 million, or $0.25 per share, diluted, for the comparable period in 2020.
Exelixis
Exelixis
Exelixis Revenue by Segment
Forward Guidance
Exelixis is providing the following updated financial guidance for fiscal year 2021: Total revenues $1,300 million - $1,400 million and Net product revenues $1,050 million - $1,150 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income